Literature DB >> 9182119

Combination of 5-flucytosine and capsule-binding monoclonal antibody in the treatment of murine Cryptococcus neoformans infections and in vitro.

M Feldmesser1, J Mukherjee, A Casadevall.   

Abstract

The efficacy of combination therapy with 5-flucytosine and an IgG1 monoclonal antibody to Cryptococcus neoformans capsular glucuronoxylomannan was studied in vitro with J774. 16 murine macrophage-like cells and in vivo in murine cryptococcal infection. The combination of 5-flucytosine and IgG1 was more effective in reducing the numbers of C. neoformans colony-forming units in vitro and in vivo than either agent alone.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 9182119     DOI： 10.1093/jac/37.3.617

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  10 in total

1.  Characterization of a flocculation-like phenotype in Cryptococcus neoformans and its effects on pathogenesis.

Authors:  Li Li; Oscar Zaragoza; Arturo Casadevall; Bettina C Fries
Journal:  Cell Microbiol       Date:  2006-06-07       Impact factor: 3.715

Review 2.  Biosynthesis and immunogenicity of glucosylceramide in Cryptococcus neoformans and other human pathogens.

Authors:  Ryan Rhome; Travis McQuiston; Talar Kechichian; Alicja Bielawska; Mirko Hennig; Monica Drago; Giulia Morace; Chiara Luberto; Maurizio Del Poeta
Journal:  Eukaryot Cell       Date:  2007-08-10

3.  Identification and characterization of Cryptococcus neoformans protein fractions that induce protective immune responses.

Authors:  Ashok K Chaturvedi; Susan T Weintraub; Jose L Lopez-Ribot; Floyd L Wormley
Journal:  Proteomics       Date:  2013-12       Impact factor: 3.984

4.  Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis.

Authors:  Robert A Larsen; Peter G Pappas; John Perfect; Judith A Aberg; Arturo Casadevall; Gretchen A Cloud; Robert James; Scott Filler; William E Dismukes
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

Review 5.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

6.  Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans.

Authors:  D O Beenhouwer; S Shapiro; M Feldmesser; A Casadevall; M D Scharff
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

7.  Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3.

Authors:  Scott Shapiro; David O Beenhouwer; Marta Feldmesser; Carlos Taborda; Michael C Carroll; Arturo Casadevall; Matthew D Scharff
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

8.  Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.

Authors:  A Casadevall; W Cleare; M Feldmesser; A Glatman-Freedman; D L Goldman; T R Kozel; N Lendvai; J Mukherjee; L A Pirofski; J Rivera; A L Rosas; M D Scharff; P Valadon; K Westin; Z Zhong
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

Review 9.  The capsule of the fungal pathogen Cryptococcus neoformans.

Authors:  Oscar Zaragoza; Marcio L Rodrigues; Magdia De Jesus; Susana Frases; Ekaterina Dadachova; Arturo Casadevall
Journal:  Adv Appl Microbiol       Date:  2009       Impact factor: 5.086

Review 10.  New Approaches for Cryptococcosis Treatment.

Authors:  Cristina de Castro Spadari; Fernanda Wirth; Luciana Biagini Lopes; Kelly Ishida
Journal:  Microorganisms       Date:  2020-04-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.